Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Journal of cellular and molecular medicine - 1 Feb 2009

Tefferi Ayalew

Abstract excerpt

Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPN) include BCR-ABL1 and rearranged PDGFR proteins. The latter are products of intra- (e.g. FIP1L1-PDGFRA) or inter-chromosomal (e.g. ETV6-PDGFRB) gene fusions. BCR-ABL1 is associated with chronic myelogenous leukaemia (CML)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Fusion Proteins, bcr-abl
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-abl

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Receptors, Thrombopoietin

Source

Open in PubMed Open full text

Identifiers

PMID: 19175693
DOI: 10.1111/j.1582-4934.2008.00559.x
PMCID: PMC3823350

Genes

JAK2
ABL1
FGFR1
PDGFRA
BCR
KIT
PDGFRB
ETV6
MPL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19175693-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.PMID 19175693Read ↗

Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).Semantic proximity Read ↗

Oncogenes in myeloproliferative disorders.Semantic proximity Read ↗

Genetic basis of MPN: Beyond JAK2-V617F.Semantic proximity Read ↗

Mutations in myeloproliferative neoplasms - their significance and clinical use.Semantic proximity Read ↗

Chronic myeloproliferative disorders: a tyrosine kinase tale.Semantic proximity Read ↗

JAK and MPL mutations in myeloid malignancies.Semantic proximity Read ↗

Molecular genetic evaluation of myeloproliferative neoplasms.Semantic proximity Read ↗

[Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].Semantic proximity Read ↗

Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersSemantic proximity Read ↗

Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case ReportSemantic proximity Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.